- A Case of Lichenoid Drug Eruption Associated with Imatinib Mesylate
-
Seol JE, Park SH, Kim DH, Kim H, Kang JN
- KMID: 2396849
- Korean J Dermatol.
- 2017 Nov;55(9):621-622.
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Exacerbation of Psoriasis after Imatinib Mesylate Treatment
-
Shim JH, Oh SH, Jun JY, Kim JH, Park HY, Park JH, Lee DY
- KMID: 2164660
- Ann Dermatol.
- 2016 Jun;28(3):409-411.
- doi: 10.5021/ad.2016.28.3.409
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Loeffler endocarditis in chronic eosinophilic leukemia with FIP1L1/PDGFRA rearrangement: full recovery with low dose imatinib
-
Kim DS, Lee S, Choi CW
- KMID: 2411596
- Korean J Intern Med.
- 2018 May;33(3):642-644.
- doi: 10.3904/kjim.2016.100
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Imatinib Mesylate-Induced Hyperpigmentation of the Nose and Palate
-
Song HS, Kang HY
- KMID: 2265603
- Ann Dermatol.
- 2014 Aug;26(4):532-533.
- doi: 10.5021/ad.2014.26.4.532
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Imatinib-induced hepatitis treated by corticosteroids in a patient with metastatic gastrointestinal stromal tumor
-
Kang MK, Lee HJ, Choi JH
- KMID: 2449330
- Yeungnam Univ J Med.
- 2019 May;36(2):155-158.
- doi: 10.12701/yujm.2019.00115
Imatinib mesylate is currently used as the first-line treatment for metastatic gastrointestinal stromal tumors (GISTs). Imatinib-induced hepatotoxicity in patients with GIST is very rare. Its features vary from subclinical elevation... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Drug Eruption with Localized ExfoliativeDermatitis Induced by Imatinib Mesylate
-
Yoo KH, Rho YK, Kim JY, Li K, Seo SJ, Hong CK
- KMID: 2248087
- Korean J Dermatol.
- 2008 Oct;46(10):1435-1438.
Imatinib mesylate (Gleevec(R), formerly known as STI571) is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase created by the Philadelphia chromosome abnormality in patients with chronic myeloid leukemia... -
- CITED
-
- Close
- SHARE
-
- Close
- Postoperative Cure for Metastatic Gastrointestinal Stromal Tumor
-
Park EH, Kim JI, Cheung DY, Park SH
- KMID: 2428015
- Korean J Helicobacter Up Gastrointest Res.
- 2018 Dec;18(4):264-270.
- doi: 10.7704/kjhugr.2018.18.4.264
Gastrointestinal stromal tumor (GIST) is a mesenchymal tumor derived from Cajal cells originating from the myotonic plexus. The expression of tyrosine kinase (KIT) membrane receptors that are active on KIT... -
- CITED
-
- Close
- SHARE
-
- Close
- Imatinib Mesylate-Induced Erythema Multiforme: Recurrence after Rechallenge with 200 mg/day Imatinib
-
Lee MK, Kwon WJ, Cho EB, Park EJ, Kim KH, Kim KJ
- KMID: 2171478
- Ann Dermatol.
- 2015 Oct;27(5):641-643.
- doi: 10.5021/ad.2015.27.5.641
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Pityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec(TM))
-
Cho AY, Kim DH, Im M, Lee Y, Seo YJ, Lee JH
- KMID: 2171872
- Ann Dermatol.
- 2011 Dec;23(Suppl 3):S360-S363.
- doi: 10.5021/ad.2011.23.S3.S360
Imatinib mesylate (Gleevec(TM), STI571), a selective inhibitor of BCR-ABL, c-Kit, and platelet-derived factor receptor, has been used to treat chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors. Although its use... -
- CITED
-
- Close
- SHARE
-
- Close
- Two different KIT mutations may lead to different responses to imatinib in metastatic gastrointestinal stromal tumor
-
Yim E, An HJ, Cho U, Kim Y, Kim SH, Choi YG, Shim BY
- KMID: 2411555
- Korean J Intern Med.
- 2018 Mar;33(2):432-434.
- doi: 10.3904/kjim.2015.295
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Psoriasiform Drug Eruption Induced by Imatinib Mesylate (GleevecTM)
-
Bae YI, Yun SJ, Lee JB, Kim SJ, Lee SC, Won YH
- KMID: 2247824
- Korean J Dermatol.
- 2009 Jun;47(6):722-725.
Imatinib mesylate (GleevecTM, formerly known as STI571) is an oral drug that selectively inhibits bcr-abl, c-kit and platelet-derived factor receptor (PDGFR) tyrosine kinase. It has been used for treating chronic... -
- CITED
-
- Close
- SHARE
-
- Close
- Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia
-
Kavanagh S, Bril V, Lipton JH
- KMID: 2451040
- Blood Res.
- 2018 Jun;53(2):172-174.
- doi: 10.5045/br.2018.53.2.172
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Complete remission of philadelphia chromosome-positive acute myeloid leukemia with imatinib mesylate
-
Jang SB, Bae SH, Jung HR, Yoon SY, Jun EJ, Kang GW, Ryoo HM
- KMID: 2259216
- Korean J Med.
- 2010 Jan;78(1):132-137.
Philadelphia chromosome-positive acute myeloid leukemia (Ph+AML) is a rare disease characterized by a poor prognosis with resistance to standard chemotherapy. We report a patient with Ph+AML with a minor BCR-ABL-positive... -
- CITED
-
- Close
- SHARE
-
- Close
- Plantar Keratoderma with Pachyonychia Likely Induced by Imatinib Mesylate
-
Kim HO, Lee BI, Lee JY, Park YM
- KMID: 2265085
- Ann Dermatol.
- 2013 Nov;25(4):526-528.
- doi: 10.5021/ad.2013.25.4.526
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Imatinib-mesylate associated Hypersensitivity Pneumonitis
-
Lee JW, Kim HJ, Kim KJ, Shin KC, Hong YH, Chung JH, Lee KH
- KMID: 2318684
- Tuberc Respir Dis.
- 2005 Oct;59(4):423-426.
Imatinib-mesylate (Gleevec, Glivec) is a protein-tyrosine kinase inhibitor that inhibits the Bcr-Abl tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib is also used to treat patients with... -
- CITED
-
- Close
- SHARE
-
- Close
- Reversal of Marrow Fibrosis Following Imatinib Mesylate Therapy in a Patient with Chronic Myelogenous Leukemia Who Was Refractory to Interferon-alpha
-
Kim YS, Kim TH, Kim WC, Jeon YJ, Kil UH, Lee HK, Kim YS, Rho SY, Cho SG
- KMID: 2252349
- Korean J Hematol.
- 2005 Jun;40(2):124-128.
- doi: 10.5045/kjh.2005.40.2.124
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Imatinib-Mesylate Induced Interstitial Pneumonitis in Two CML Patients
-
Kim TH, Kim BG, Cho SW, Cho SK, Kim HJ, Yuh YJ, Kim SR
- KMID: 2319555
- Tuberc Respir Dis.
- 2011 Sep;71(3):210-215.
Imatinib mesylate, a selective inhibitor of BCR-ABL kinase activity, has demonstrated significant clinical efficacy in the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). It has become... -
- CITED
-
- Close
- SHARE
-
- Close
- A rare case of osteonecrosis of the jaw related to imatinib
-
Viviano M, Rossi M, Cocca S
- KMID: 2377016
- J Korean Assoc Oral Maxillofac Surg.
- 2017 Apr;43(2):120-124.
- doi: 10.5125/jkaoms.2017.43.2.120
Osteonecrosis of the jaw (ONJ) is commonly described as an adverse effect of the use of bisphosphonates. A few cases of ONJ associated with tyrosine kinase inhibitors (sunitinib, imatinib) have... -
- CITED
-
- Close
- SHARE
-
- Close
- Imatinib Mesylate Induced Acquired Dermal Melanocytosis
-
Kim EK, Jung KE, Kim HS, Park YM, Kim HO, Lee JY
- KMID: 2301602
- Korean J Dermatol.
- 2012 Aug;50(8):747-750.
Dermal melanocytosis is most commonly found in the skin of Asians and other darkly pigmented populations. It is histologically characterized by the presence of ectopic melanocytes in the dermis. Mongolian... -
- CITED
-
- Close
- SHARE
-
- Close
- Imatinib mesylate-induced interstitial lung disease in a patient with prior history of Mycobacterium tuberculosis infection
-
Lee NR, Jang JW, Kim HS, Yhim HY
- KMID: 2366019
- Korean J Intern Med.
- 2015 Jul;30(4):550-553.
- doi: 10.3904/kjim.2015.30.4.550
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
